🇺🇸 FDA
Patent

US 8809310

Use of rasagiline for the treatment of multiple system atrophy

granted A61KA61K31/13A61K31/135

Quick answer

US patent 8809310 (Use of rasagiline for the treatment of multiple system atrophy) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/13, A61K31/135, A61K31/191, A61K31/195